This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Intravitreal dexamethasone in diabetic macular oedema (DMO) - enhancing the response to anti-VEGF in non- or poor responders

Intravitreal dexamethasone in diabetic macular oedema (DMO) - enhancing the response to anti-VEGF in non- or poor responders
Reviewed by Sofia Rokerya

3 February 2023 | Sofia Rokerya | EYE - Vitreo-Retinal | Aflibercept, Anti-VEGF, Dexamethasone implant, Diabetic macular oedema, Persistent, Ranibizumab, Resistant
Share This

This study aimed to describe the outcomes of a switch back from DEXi (dexamethasone implant) to anti-VEGF therapy in eyes that were treated temporarily with DEXi after an initial poor response to anti VEGF. Twenty-three eyes of 17 patients were included. These were unresponsive to anti-VEGF and switched to a DEXi after a mean of 12 anti-VEGF injections, and then back to anti- VEGF. The mean age of the cohort at baseline was 68.1 ±8.2 years. The mean duration of diabetes was 19.3 ±9.2 years. The mean time between the last DEXi and the switch back to anti-VEGFs was 4.2 ±1.2 months. The mean best corrected visual acuity (BCVA) increased from 0.25 ±0.19 (decimals) to 0.29 ±0.20 after switching to the DEXi (p=0.11). BCVA remained stable (0.31 ±0.23; p=0.11) after switching back to anti-VEGF, one month after the last injection. The mean central macular thickness (CMT) decreased significantly from 517.0 ±128.5μm to 343.4 ±118.9μm (p<0.001) after switching to the DEXi. In eyes receiving ≥three anti-VEGF injections during the switch back, the CMT one month after the last anti-VEGF injection was significantly decreased compared to the CMT before the switch to the DEXi (a mean change of - 95.55 ±89.82μm, p=0.005). The mean intraocular pressure (IOP) was 17.2 ±3.8 mmHg at baseline, similar to 18.1 ±4.1mmHg two months after the first DEXi (p=0.22) and 18.1 ±4.2mmHg two months after the last DEXi (p=0.84). IOP significantly decreased one month after the last anti-VEGF injection of the switch back (mean IOP 13.3 ±3.6mmHg, p=0.005). The proportion of patients with ocular hypertension (ocular hypertension defined by IOP ≥21mmHg) was 20% at baseline, 13% two months after the first DEXi (p=0.53), 27.3% two months after the last DEXi (p=0.58), and 5.9% one month after the last anti-VEGF injection of the switch back (p=0.21). The conclusion drawn from the study was that switching back poorly responsive eyes to anti-VEGF after temporary DEXi therapy is associated with good anatomical and visual outcomes, provided that at least three anti-VEGF injections are administered. It is speculated that these favourable anatomical outcomes may be due to a “resensitisation of the retinal receptors to anti-VEGFs” by DEXi therapy. A transient use of DEXi may annihilate the effect of pro-inflammatory cytokines, “setting back the counter” to an anti-VEGF-dependent DME. Limitations of the study include limited sample size, retrospective nature and the absence of case-control comparison with eyes pursuing DEXi therapy alone.

Intravitreal dexamethasone in diabetic macular oedema: a way of enhancing the response to anti-VEGF in non- or poor responders.
Touhamia S, Dupasa B, Bertauda S, et al.
OPHTHALMOLOGICA
2022;245(4):350-7.
Share This
Sofia Rokerya
CONTRIBUTOR
Sofia Rokerya

MBBS MRCOphth FRCSI, King's College University Hospital, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency